Option chain shows key data for Astellas Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Astellas Pharma.

Astellas Pharma (OTC:ALPMF) Stock, Option Chain

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

APLS

Analyst Color

Biotech

Large Cap

News

Health Care

Price Target

Initiation

Analyst Ratings

Trading Ideas

General

ALPMF

ALPMY

William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales estimates of $700 million by 2031 for Empaveli and $2 billion for Syfovre by 2030.

Syfovre&#39;s Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

nuvb

Earnings

Movers

NUVB

Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage pipeline developments.

Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data

Word,Menopause,,Pause,Sign,On,A,White,Alarm,Clock,On

BAYRY

BAYZF

DARE

Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo.

Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval

ASTELLAS PHARMA INC by Astellas Pharma, Inc.

Astellas Pharma Inc

J&J prostate cancer therapy outperforms in real-world study

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

Pfizer reports positive Phase 3 results for Talzenna/Xtandi combo

Astellas wins FDA nod for first-line gastric cancer therapy

Astellas Pharma (JP:4503) has released an update. Astellas Pharma has received FDA approval for VYLOY, a novel treatment targeting CLDN18.2 for adv...

Astellas Pharma's VYLOY Gains FDA Approval for Cancer Treatment

Apellis a new sector perform at RBC on Syfovre expectations

Astellas Pharma (JP:4503) has released an update. Astellas Pharma has withdrawn its marketing application for avacincaptad pegol, a treatment for g...

Astellas Pharma Withdraws EU Application for Key Drug

Astellas Pharma (JP:4503) has released an update. Astellas Pharma Inc. reported a foreign exchange loss of ¥12.2 billion for the first half of FY20...

Comments

Astellas Pharma

Astellas Pharma (ALPMF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga